EU orphan status for Cell Medica drug
London, UK-based Cell Medica has received European Commission orphan drug designations for its lead cancer immunotherapy CMD-003 (baltaleucel-T).
Read More
Tag: Epstein Barr
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
